US Home Infusion Therapy Market

U.S. Home Infusion Therapy Market Size

The U.S. home infusion therapy market was estimated at USD 13.8 billion in 2024. The market is expected to grow from USD 15.1 billion in 2025 to USD 31.4 billion in 2034, growing at a CAGR of 8.4% from 2025 to 2034, according to the latest report published by Global Market Insights Inc. This high growth is attributed to several factors, including rising prevalence of chronic disorders, growing hospital acquired infections, favorable reimbursement policies, and increasing preference towards at-home healthcare solutions.

In home infusion therapy, healthcare providers administer medications and biologicals while the patient remains in the comfort of his home. This treatment model helps treat many health conditions, including infections, dehydration, cancers, gastrointestinal problems, and long-term illnesses that need regular medication. Major players in the industry include BD, Baxter, B. Braun, Fresenius, and ICU Medical, among other players. Availability of wide treatment therapies, patient comfort, and cost-effectiveness are the key variables fuelling the demand for home infusion therapies in the U.S.

The market is expanding due to rising chronic disease prevalence, including cancer, diabetes, and autoimmune disorders, which require long-term infusion treatments. For instance, researchers from the Mayo Clinic concluded a new study to estimate the prevalence of autoimmune (AI) diseases in the U.S. As per the results of the study published in the Journal of Clinical Investigation, around 15 million U.S. citizens are suffering from one or more of the 105 autoimmune disorders.

Moreover, an increasing number of patients taking treatment for various disorders in healthcare facilities get infected with hospital-acquired infections. For instance, as per the published statistics, HAIs affect 5% of the total hospitalized patients in the U.S. Some of the most common HAIs include CAUTI, C. difficile infection (CDI) and Surgical site infections (SSIs) among others. To avoid getting infected with such infections, especially in the elderly population, the patients prefer home-based infusion therapies for different indications, thereby supporting the market growth.

Further, as the population ages in the U.S., more people are developing chronic diseases and conditions that need ongoing medical treatment. Elderly patients are more susceptible to different chronic conditions as they have a compromised immunity. For example, according to the data reported by The National Council on Aging, there were around 57.8 million U.S. adults living in 2022. Thus, the growing geriatric population is projected to spur the demand for home infusion services in the U.S. throughout the analysis period.

Home infusion therapy allows patients to receive medications and biological treatments intravenously or subcutaneously while staying comfortable in their own homes. This can be performed for various indications covering oncology, gastrointestinal diseases, chronic conditions, among others.

U.S. Home Infusion Therapy Market Trends

The home infusion industry is experiencing various key trends that include growth among healthcare providers expanding their range of treatments and therapies, developing innovative infusion devices, shifting toward personalized therapy models, and enhancing specialty pharmacy services, among others.

• Healthcare providers now offer a wide range of home infusion therapies, moving beyond the basic antibiotics and hydration treatments. Patients can receive advanced treatments such as immunoglobulin therapy, chemotherapy, parenteral nutrition, and biologic therapies in their homes. This broader range of treatment options allows more patients to receive specialized care in their familiar environment, making treatment more comfortable while maintaining their quality of life.
  
• The advancement of infusion pump technology, catheters, and connected devices has made home infusion therapy safer, more accurate, and more reliable. Modern smart pumps come with integrated software that ensures precise medication delivery, allows healthcare providers to monitor treatment remotely, and collects patient data in real-time.
  
• These improvements in technology help expand home infusion services by making treatment management more efficient, lowering the risk of complications, and allowing healthcare providers to deliver personalized care to patients using various remote monitoring devices.
  
• Further, healthcare providers are increasingly opting for biologics, IVIG therapy, and antimicrobial medications for patient treatment, while improved safety features such as needleless connectors help deliver better patient care.
  

U.S. Home Infusion Therapy Market Analysis

The growing awareness levels and availability of affordable treatment, coupled with a focus on early diagnosis and timely therapeutic intervention, are anticipated to spur the industry’s growth.

Based on product, the U.S. home infusion therapy market is segmented into infusion pumps, intravenous sets, IV cannulas and needleless connectors. The infusion pumps segment accounted for a majority share of 49.8% in 2024. The consistent innovation and advancement in infusion pumps to provide accurate dosing to patients is a key factor supporting the market growth. The segment is expected to exceed USD 14.9 billion by 2034, growing at a CAGR of 7.9% during the forecast period.

• Infusion pumps assist in keeping the patients safe by delivering medications with precision thereby reducing the medication errors. These devices come with helpful features such as dose rate monitoring and alarm systems that enhance the treatment's reliability and are easier to follow.
  
• There is a significant rise in the adoption of infusion pumps by healthcare providers for both home-based therapy and facility-based therapies owing to increased focus on patient safety and better treatment outcomes. For example, in May 2025, Penlon, a medical device company, launched their new range of infusion pumps, including the SYS-70. In addition, through educational programs, awareness campaigns, and positive experiences shared by other patients, more people are opting for home infusion treatment, pushing the infusion pump segment growth.
  
• The intravenous sets segment held a considerable share and was valued at USD 1.8 billion in 2024. The growing patient population with different chronic conditions, coupled with favorable reimbursement policies, is expected to fuel the segmental growth.
  
• Further, the needleless connectors segment accounted for significant market share and is expected to witness the fastest growth with a 9.1% CAGR over the analysis period. Healthcare providers are opting for a needleless connectors in both hospitals and home care settings as they help to prevent needlestick injuries, improve infection control, among others.
  

Based on application, the U.S. home infusion therapy market is segmented into anti-infectives, hydration therapy, chemotherapy, enteral nutrition, parenteral nutrition, specialty pharmaceuticals, and other applications. The anti-infectives segment accounted for the leading market share of 27.1% in 2024, due to increasing need for infection treatment, especially among immunocompromised and elderly patients.

• The anti-infectives segment is experiencing significant growth in home infusion therapy, as more elderly patients are suffering from different infections due to their weakened immunity levels. In addition, when patients receive treatment at home, they are less likely to get infected with hospital-acquired infections. Healthcare professionals now prefer to prescribe intravenous antibiotics and antivirals at-home for conditions such as pneumonia, cellulitis, and osteomyelitis.
  
• Further, more patients are opting for home infusion therapy because it is convenient, cost-effective, and helps them recover in the comfort of their own home.
  
• Availability of better infusion devices and remote monitoring systems has made treatments safer and easier to follow. As healthcare providers expand their outpatient services and improve their delivery and nursing support, doctors feel more confident prescribing anti-infective treatments to at home patients.
  
• Moreover, the enteral nutrition segment held a significant share and was valued at USD 3.5 billion in 2024. The U.S. home infusion therapy market shows a growing need for enteral nutrition as the percentage of people suffering from different gastrointestinal disorders, cancer, and neurological conditions is rising. More patients now choose to receive their long-term nutritional support in the comfort of their own home.

South Atlantic Home Infusion Therapy Market

South Atlantic zone dominated the U.S. home infusion therapy market with the leading market share of 20.5% in 2024.

• Major states in the South Atlantic zone such as Florida, Georgia and North Carolina among others, have a significant patient population suffering from different types of cancers. Many patients with these conditions need long-term intravenous (IV) treatments, making home infusion therapy services essential for their care. For instance, according to the data reported by Florida Health in 2025, cancer has been the second leading cause of death in the state since 2014.
  
• In addition, the data also highlighted the number of cancer-related deaths in Florida between 2021 and 2023, which was over 140 thousand. Thus, home infusion therapy plays a key role in offering treatment to such a high patient population across the state.
  
• Further, the introduction of easy-to-use, portable infusion pumps has made it simpler and safer for patients to receive their treatments in the comfort of their homes. Thus, the rising incidence of such chronic conditions drives the demand for home infusion therapy across the zone.
  

Pacific Central Home Infusion Therapy Market

Pacific Central home infusion therapy market accounted for around USD 2.3 billion in 2024.

• The Pacific Central zone includes various states such as California, Washington, etc., which are home to numerous urban centers with modern healthcare facilities, offering patients easier access to home infusion services.
  
• California, a major state in the zone, accounts for a significant percentage of the total diabetic population in the country. For instance, according to the data reported by the American Diabetes Association, there were over 3 million people suffering from diabetes in California in 2023. The annual cost of diagnosed diabetes is estimated at USD 39.5 billion in the state. Thus, the significantly high target population makes it necessary to opt for home-based infusion therapies, including the adoption of remote monitoring and smart infusion devices.
  
• Further, as more people in the region age and develop chronic health conditions, they need long-term infusion treatments at home. Local healthcare regulations and insurance coverage make it possible for healthcare providers to offer better home care options to their patients.
  
• Furthermore, demand for personalized healthcare that focuses on the individual needs of the patient makes home infusion care a go-to choice, helping the region to become an important market for these services.
  

Northeast Home Infusion Therapy Market

The Northeast home infusion therapy market is anticipated to witness notable growth over the analysis timeframe.

• The Northeast region shows remarkable growth in home infusion therapy, owing to the high zonal population, strong healthcare awareness, and well-developed medical infrastructure.
  
• The zone is home to a significant percentage of elderly residents and a high number of people living with chronic diseases. Key states in the region, such as New York, New Jersey, and Pennsylvania among others, have a considerable patient population suffering from different cardiovascular ailments. Such conditions need timely and regular therapeutic intervention, due to which the region records an increasing need for long-term infusion treatments at home.
  
• Further, better insurance coverage and new ways of delivering care help expand these services across the region. The demand for a personalized treatment approach works hand-in-hand with the benefits of home infusion therapy.
  

U.S. Home Infusion Therapy Market Share

Leading industry players such as BD, Baxter, B. Braun, Fresenius, and ICU Medical hold around 20-25% of the market share in the competitive U.S. home infusion therapy market. These companies maintain their leading position by combining a strong product and service portfolio, regulatory clearances, enhanced distribution channels, and consistent product innovation.

The market features a diverse range of players, from major healthcare companies to specialized home infusion providers and regional healthcare organizations. These organizations actively work to expand their reach, improve their services, and build partnerships to strengthen their position in the market.

Innovation and competition thrive through advances in technology, especially in infusion pumps and telehealth solutions. Additionally, local providers and specialized companies play an important role by delivering personalized care and specialized services, thereby creating a competitive marketplace.

Further, notable investments in research and development, partnerships, and integration of the existing product range with digital tools are among a key business strategy. Companies are working to improve the overall patient experience throughout the infusion therapy.

U.S. Home Infusion Therapy Market Companies

Few of the prominent players operating in the U.S. home infusion therapy industry include:

• Key players
  • B. Braun
  • Baxter
  • BD
  • Fresenius
  • ICU Medical
  • LEPU MEDICAL
  • McKESSON
  • MOOG
  • TERUMO
• Emerging players
  • AMSINO
  • AVANOS
  • CONTEC
  • DAIWHA
  • ERENLER MEDIKAL
  • JMS
    
• BD

BD leads the U.S. home infusion therapy market with a share of around 6% in 2024 due to company’s robust and advanced product portfolio. BD is working towards enhancing its smart infusion systems by integrating them with data analytics capabilities that help improve patient safety and compliance. By building stronger partnerships with home care providers and developing portable, easy-to-use devices, the company can better serve its market needs. Making products that are both environmentally friendly and cost-effective is another key variable in company's business strategy.

• B. Braun

B. Braun is focusing on development of better needle-free and antimicrobial infusion technologies with a target of providing enhanced safety for the patients. Improving its distribution networks and support systems for home care is a key area of focus for the company. Further, integrating digital tools to improve the overall patient experience is a key strategy.

• Baxter

Baxter is utilizing its knowledge of IV solutions and infusion pumps to develop portable, compact, and connected devices that can be easily adapted in at-home settings. In addition. The company is working with telehealth providers to offer better treatment options, especially for long-term conditions, which will assist in fulfilling the growing patient needs.

U.S. Home Infusion Therapy Industry News:

• In April 2025, ICU Medical, a medical devices manufacturing company, announced that they have received the FDA 510(k) regulatory clearance for their Plum Solo precision IV pump. The company also received the clearances for Plum Duo precision IV pump and LifeShield infusion safety software. With these clearances, the company is focusing on introducing a new category of its precision IV pumps, fueling the business growth.
  
• In April 2024, Baxter International Inc. announced that the company has received FDA clearance for its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software. This development enabled the company to expand its product range and improve the sales prospect in the coming years.
  
• In December 2023, B. Braun announced the launch of its new CARESITE Micro Luer Access Device. This needleless connector is designed to reduce exposure to harmful chemicals and decrease infection risk and is not made with Bisphenol A (BPA). This development allowed the company to improve its industry presence through expanded product range in the U.S.
  

The U.S. home infusion therapy market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Infusion pumps
• Intravenous sets
• IV cannulas
• Needleless connectors

Market, By Application

• Anti-infectives
• Hydration therapy
• Chemotherapy
• Enteral nutrition
• Parenteral nutrition
• Specialty pharmaceuticals
• Other applications

The above information is provided for the following zones and states:

• East North Central
  • Illinois
  • Indiana
  • Michigan
  • Ohio
  • Wisconsin
• West South Central
  • Arkansas
  • Louisiana
  • Oklahoma
  • Texas
• South Atlantic
  • Delaware
  • Florida
  • Georgia
  • Maryland
  • North Carolina
  • South Carolina
  • Virginia
  • West Virginia
  • Washington, D.C.
• Northeast
  • Connecticut
  • Maine
  • Massachusetts
  • New Hampshire
  • Rhode Island
  • Vermont
  • New Jersey
  • New York
  • Pennsylvania
• East South Central
  • Alabama
  • Kentucky
  • Mississippi
  • Tennessee
• West North Central
  • Iowa
  • Kansas
  • Minnesota
  • Missouri
  • Nebraska
  • North Dakota
  • South Dakota
• Pacific Central
  • Alaska
  • California
  • Hawaii
  • Oregon
  • Washington
• Mountain States
  • Arizona
  • Colorado
  • Utah
  • Nevada
  • New Mexico
  • Idaho
  • Montana
  • Wyoming